Loren Data's SAM Daily™

FBO DAILY - FEDBIZOPPS ISSUE OF SEPTEMBER 16, 2016 FBO #5411
SOLICITATION NOTICE

Q -- Whole Exome Sequencing of Naturally Occurring Canine Melanoma Tumors and Patient-Matched Normal Tissues.

Notice Date

9/14/2016
 

Notice Type

Presolicitation
 

NAICS

325414 — Biological Product (except Diagnostic) Manufacturing
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
 

ZIP Code

20852
 

Solicitation Number

N02RC62704-61
 

Archive Date

10/3/2016
 

Point of Contact

KATHY D. ELLIOTT, Phone: 240-276-5570, Seena Ninan, Phone: 240-276-5419
 

E-Mail Address

ELLIOTTK@MAIL.NIH.GOV, ninans@mail.nih.gov
(ELLIOTTK@MAIL.NIH.GOV, ninans@mail.nih.gov)
 

Small Business Set-Aside

N/A
 

Description

Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E224, Rockville, MD 20850, UNITED STATES. 1. Description The National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Cancer Biology and Genetics (LCBG), Molecular Pathology Unit (MPU) plans to procure sequencing services to analyze Whole Exome Sequencing of Naturally Occurring Canine Melanoma Tumors and Patient-Matched Normal Tissues from Otogenetics Corporation, 45553 Winters Chapel Road, Suite 100, Atlanta, Georgia 30360. The response close date of this notice for this requirement is in accordance with FAR 5.203(a)(1). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1), and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 325414 and the business size standard is 1,250. It has been determined there are no opportunities to acquire green products or services for this procurement. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. 2. Background The Laboratory of Cancer Biology and Genetics (LCBG) self-assembled in 2006 through the merger of the Laboratory of Cellular Carcinogenesis and Tumor Promotion (LCCTP), the Laboratory of Cell Regulation and Carcinogenesis (LCRC) and the Laboratory of Genetics (LG). The LCBG currently encompasses the work of 12 principal investigators supervising independent research programs with highly overlapping experimental goals and approaches. These investigators conduct a well-integrated research program consisting of basic and translational components that are designed to: elucidate the cellular and tissue changes associated with specific stages of carcinogenesis, detect and characterize genetic modifiers fundamental to cancer susceptibility and progression, define the molecular mechanisms involved in the pathogenesis of major human cancers, and develop rational approaches for cancer prevention and treatment. Studies are performed in vivo in animal models, in vitro in cell and organ culture, and on tissues and cells obtained from human volunteers and cancer patients. The LCBG also develops and correlates novel protocols in molecular diagnostics for human and animal tissues, and in noninvasive medical imaging for animal models. Emanating from our studies are new therapeutic combinations for targeted cancers now in clinical trials. Massively parallel (next generation) genome (whole exome) sequencing generation and bioinformatics analysis for canine melanoma. This acquisition will provide NCI the ability to validate comparisons with human cancer and benefit NCI human disease modeling and development of cancer therapies for humans and dogs with melanoma. Designing cancer therapies increasingly relies upon discovery of genetic derangements in cancer. DNA sequence analysis of cancer tissues provides insight into the underlying causes of cancer growth and malignant potential. Current knowledge of the genetic aberration in signal transduction pathway activation in mucosal melanoma is deficient for both human beings and dogs. Naturally occurring melanoma in the dog provides a valuable model for the disease in humans. Therefore, sequence analysis of canine melanomas will provide additional insight into creating more predictive therapies for humans and dogs. Quality control and genomic DNA extraction for 55 canine samples including tumor and normal tissues, blood, and cell lines from dogs. Library preparation, probe capture and DNA exome sequencing for 31 snap frozen canine melanoma tumor tissues and cell lines (preparation for average exome capture coverage 150X) and 24 snap frozen matching normal tissues and blood (average exome coverage 50X normal). Analysis to include bioinformatics mapping and alignment, sequence variation and SNP identification in 7 canine melanoma cell lines. Contractor Tasks shall be as follows: 1. Quality control (QC) of DNA extractions. 2. Capture of DNA sample species. 3. Preparation of the genomic species library. The output shall be to 15 - 16 Gigabases and average 150 X times coverage for 31 dog tumor samples. The output shall be to 5.4 - 6 Gigabases and average 50 X times coverage for 24 dog normal tissue samples (patient matched control tissue or blood). 4. Generation of sequence reads using high throughput sequencing technology. 5. Analysis of sequence generated from 7 canine cell lines must be processed by bioinformatics methods against the published canine canFam3 database and include: mapping and alignment (BAM file), quality control coverage, sequence variation (SNPs/insertion and deletion report (.VCF file)), vcf annotations, functional prediction and population frequency. 6. Guarantee sufficient target coverage for data interpretation. 7. Retain the output sequence data on a secured server with back up for an extended period to ensure access to data in case data is lost due to unforeseen circumstances. 8. Provide technical support available by phone or email. PLACE OF PERFORMANCE: Sequencing generation and bioinformatics analysis for canine melanoma will be performed in accordance with the manufacturer's standard commercial practices. PERIOD OF PERFORMANCE: The period of performance shall be 4-6 weeks to deliver from date of award. PAYMENT: Payment shall be made after sample tracking for each specimen from receiving to data and report delivery, lab approval and submission of invoice to the address shown in Block 21 of the purchase order. CONTRACT TYPE: Firm Fixed Price QUESTIONS ARE DUE: September 16, 2016 at 11:00 AM, EST. This is not a solicitation for competitive quotations. However, if any interested parties, especially small businesses, believe they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. A copy of the capability statement must be received in the NCI Office of Acquisition on or before 2:00 PM EST on September 18, 2016. All questions must be in writing and can be faxed (240) 276-5401 or emailed to Kathy Elliott, Contract Specialist at Elliottk@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification on Sam.gov, www.sam.gov. No collect calls will be accepted. Please reference solicitation number N02RC62704-61 on all correspondence.
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC62704-61/listing.html)
 

Place of Performance

Address: 9000 Rockville Pike, Bethesda, Maryland, 20892, United States

Zip Code: 20892
 

Record

SN04270464-W 20160916/160914234355-2881d7fc8461e74fd9fd8bc3c73779ec (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |